Eton Pharmaceuticals, Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
ETON$56.46+19.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · INDICATION
INDICATION
GALZIN® (zinc acetate) is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.